JPRN-UMIN000004731已完成2 期
Phase II study of carboplatin and pemetrexed plus bevacizumab after failure of first-line EGFR TKI therapy for non-small-cell lung cancer harboring EGFR mutation. - Phase II study of carboplatin and pemetrexed plus bevacizumab after failure of first-line EGFR TKI therapy for non-small-cell lung cancer harboring EGFR mutation.
Central Japan Lung Study Group0 个研究点目标入组 27 人开始时间: 2010年12月15日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 27
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Symptomatic brain metastasis 2)Hemoptysis (>=2.5ml) 3)Tumor invasion to the large blood vessel 4)Uncontrolled hypertension 5)Active infection 6)Severe underlying disease such as uncontrolled heart disease or diabetes mellitus 7)Receiving anticoagulants 8)Other concurrent active malignancy 9)Superior vena cava syndrome 10)Massive pleural or pericardial effusion, or ascites 11)Vertebral metastases requiring radiation therapy 12)Severe drug allergy 13)Active GI bleeding or inflammation in the abdominal cavity 14)Major surgery within 4 weeks 15)Pregnant or breast-feeding woman
研究者
相似试验
已完成
2 期
Phase II study of Pemetrexed and Carboplatin plus Bevacizumab for advanced non-small cell lung cancernon-squamous non-small-cell lung cancerJPRN-UMIN000003680ippon Medical School Hospital26
已完成
2 期
Phase II study of Pemetrexed + Carboplatin as first line therapy for nonsquamous non-small cell lung cancer with interstitial pneumoniaJPRN-UMIN000011325Central Japan Lung Study Group (CJLSG)25
已完成
2 期
A Phase 2 study of pemetrexed and carboplatin for platinum-pretreated patients with non small cell lung cancerplatinum pretreated patients with non small cell lung cancerJPRN-UMIN000005552Osaka Prefectural Medical Center for Respiratory and Allergic deseases30
招募中
2 期
A Phase II study of Pemetrexed plus Carboplatin Plus Bevacizumab followed by maintenance Pemetrexed in patients with previously untreated stage III/IV or non-squamous non-small-cell and lung cancer.on-squamous non-small cell lung cancer (EGFR mutation status Negative)JPRN-UMIN000005991Toho University Omori Medical Center35
已完成
2 期
A Phase II study of Pemetrexed plus Carboplatin Plus Bevacizumab followed by maintenance Pemetrexed Plus Bevacizumab in patients with previously untreated stage III/IV or post-operative recurrent non-squamous non-small-cell and lung cancer.on-squamous non-small cell lung cancerJPRN-UMIN000003770Osaka Lung Cancer Study Group40